Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Head and Neck Cancers

Although head and neck cancer is a common malignancy, there are few programs in the country that have dedicated, multidisciplinary teams to treat a large number of patients. The Vanderbilt-Ingram Cancer Center has a nationally recognized Head and Neck Cancer Program which is staffed by expert surgeons, a full-time medical oncologist and full-time radiation oncologists.

Clinical Trials for Head and Neck Cancers

17 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

VICCHN0603

04/28/2006

Effect of PI3K Inhibition in HPV Infected Cell (deidentified)

Basic Science

VICCHN0529

05/10/2005

Novel Protein Regulator of Tumor Suppressor ARF & NF-kB (NIH/2 R01 DEO13173-05) (deidentified)

Basic Science

VICCHN0530

04/08/2005

Serum Biomarkers for Head & Neck Cancer (deidentified)

Basic Science

VICCHN0356

02/04/2003

Head and Neck Tumor Tissue Repository and Clinical Database

Health Services Research

VICCHN14122

12/23/2014

A Pilot Study for a Pain Management Smartphone Application for Patients Undergoing Radiation Therapy for Locally Advanced Head and Neck Cancer

Other

VICCSUPP1517

10/16/2015

A Qualitative Study to Explore Patients' Experience of Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Evaluate Relevant Patient-Reported Outcome Measures for Clinical Trials

Other

VICCSUPP1530

04/14/2015

A Patient-Centered Outcomes Study of Patients with Recurrent Head and Neck Cancer

Supportive Care

VICCHN1541

07/01/2015

A Randomized Phase III Trial of Gabapentin versus Standard of Care for Prevention and Treatment of Mucositis in Locally Advanced Head and Neck Cancer Patients Undergoing Primary or Adjuvant Chemoradiation

Supportive Care

VICCSUPP1529

06/08/2015

Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients

Treatment

VICCHN1575

01/08/2016

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Treatment

VICCPHI1598

12/10/2015

A Phase 1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 and MM-121 in Heregulin Positive Cancer Patients

Treatment

VICCHN1576

12/04/2015

A Phase 2 Study of TH-4000 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

Treatment

VICCPHI1588

11/27/2015

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

Treatment

VICCHN14139

10/08/2015

A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Reucurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).

Treatment

VICCHN14121

04/23/2015

A Phase II Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Treatment

ECOGHNE3311

08/29/2014

Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

Treatment

ECOGHNE1305-M

02/11/2009

A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer